Alkaloids are a class of organic compounds with a wide range of biological properties, including anti-HIV activity. The 1,2,3,4-tetrahydroisoquinoline is a ubiquitous structural motif of many alkaloids. Using a short and an efficient route for synthesis, a series of 1,2,3,4-tetrahydroisoquinolines/isoquinolines was developed. These compounds have been analysed for their ability to inhibit an important interaction between HIV-1 integrase enzyme (IN) and human LEDGF/p75 protein (p75) which assists in the viral integration into the active genes. A lead compound 6d is found to inhibit the LEDGF/p75-IN interaction in vitro with an IC 50 of ~10 μm. Molecular docking analysis of the isoquinoline 6d reveals its interactions with the LEDGF/p75-binding residues of IN. Based on an order of addition experiment, the binding of 6d or LEDGF/p75 to IN is shown to be mutually exclusive. Also, the activity of 6d in vitro is found to be unaffected by the presence of a non-specific DNA. As reported earlier for the inhibitors of LEDGF/p75-IN interaction, 6d exhibits a potent inhibition of both the early and late stages of HIV-1 replication. Compound 6d differing from the known inhibitors in the chemical moieties and interactions with CCD could potentially be explored further for developing small molecule inhibitors of LEDGF/ p75-IN interaction having a higher potency.
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HIV-1 integrase, inhibition, interaction, isoquinoline, LEDGF/p75 | GEORGE Et al. core domain) of IN reveals that two interhelical loops of IBD, comprised of the residues 364-368 and 405-408, respectively, interact with the LEDGF-binding site at the dimer interface of CCD of IN. [13, 21, 22] The hydrophobic interaction [24] [25] [26] [27] [28] [29] [30] The ALLINIs present during the late phase of HIV-1 replication induce a premature multimerization of IN (a LEDGF/p75-independent effect) resulting in the production of less infectious virions that are defective for reverse transcription, nuclear import of PIC and integration. [31] [32] [33] The LEDGINs such as GS-A and GS-B also qualify as noncatalytic site IN inhibitors (NCINIs) as they interfere with IN-vDNA assembly. [24, 27] The LEDGF/p75-independent effects of these molecules are found to contribute to their higher potency for inhibiting HIV-1 replication. In this study, starting with a series of 1,2,3,4-tetrahydroi soquinolines, a non-halogenated isoquinoline compound 6d has been identified as a lead molecule for inhibiting LEDGF/ p75-IN interaction. The chosen tetrahydroisoquinoline moiety is present in a number of isoquinoline-based alkaloid natural products having antitumour, antimicrobial, antiinflammatory, anti-analgesic and anti-HIV-1 activity. [34] [35] [36] A short and efficient route for the synthesis of substituted 1,2,3,4-tetrahydroisoquinolines was developed in an earlier study and shown to yield pure compounds suitable for biological evaluation. [37, 38] Following an initial screening of the series of tetrahydroisoquinolines, a lead compound 6d with an IC 50 of ~10 μm for inhibiting in vitro interaction between recombinant LEDGF/p75 and IN was obtained. Compared to the LEDGF/p75-IN inhibitors reported earlier, [23] [24] [25] [26] [27] [28] [29] [30] 6d differs in: having an isoquinoline rather than a quinoline core, lacking a halogen or sulphur atom and having an ester rather than a carboxyl moiety ( Figure S1 ). As seen in the threedimensional structures of known LEDGINs bound to the CCD dimer, [23, 24] molecular docking analysis shows 6d interacting with the LEDGF/p75 binding site of a CCD dimer, although the type of interactions is different. Both IN and LEDGF/p75 can bind to DNA in a sequence-independent manner; [39] [40] [41] [42] [43] however, the presence of a non-specific DNA did not alter the inhibitory activity of 6d in vitro. Also, the preformed LEDGF/p75-IN complexes could not be disrupted by 6d in vitro, indicating a requirement for 6d to access the LEDGF/p75-binding site on IN for having an inhibitory effect. Interaction of LEDGF/p75 and IN in the cell lysates, as well as the early and late stages of HIV-1 replication, is efficiently inhibited by 6d. Taken together, the unique features of 6d described here could potentially be used for developing inhibitors of LEDGF/p75-IN interaction having a higher potency.
| METHODS AND MATERIALS

| Synthesis of 1,2,3,4-tetrahydroisoquinoline compounds
The synthesis of 1,2,3,4-tetrahydroisoquinoline compounds 1a-1m ( Figure S2 ) was performed as described earlier. [37, 38] The reduced ester moiety of 1a (labelled 4a) and rearranged aromatization of compounds 1a, 1d (labelled 6a, 6d) were synthesized as described in the Supplementary Material.
| In vitro pull-down assay
The pull-down assay using a purified C-terminus His-tagged IN (His-IN) and a N-terminus GST-tagged IBD (IBD, GST-IBD) or a N-terminus GST-tagged full-length LEDGF/p75 (GST-p75) was performed as described earlier. [44] Briefly, in a 150 μl of phosphate pull-down buffer (PPD buffer) having 50 mm phosphate buffer (pH 6.5), 150 mm NaCl, 2 mm MgCl 2 , 25 mm immidazole and 0.1% NP-40, with or without indicated amount of a given compound, a 3 μg of His-IN was added and incubated at 37°C for 10 min. This was followed by addition of a 3 μg of GST-IBD or GST-p75, and incubation was continued at 37°C for another 10 min. The formed complexes were pull-down by binding to the Ni Sepharose 6 Fast flow beads (GE Healthcare) for 30 min at room temperature. The bound complexes were eluted in the PPD buffer containing 400 mm immidazole and resolved on a 10% SDS-PAGE gel. Intensity of the Coomassie Blue stained protein bands was quantified using an image lab Software 4.0 (BioRad). A stock solution of all the compounds was prepared in DMSO. The required dilutions of the compounds were prepared in the PPD buffer just prior to the assay.
| Pull-down of ectopically expressed proteins from a mammalian cell lysate
Pull-down of a Flag-tagged IN (Flag-IN) and a HA-tagged LEDGF/p75 (HA-p75) overexpressed in the HEK293T cell line was performed as described earlier, [45, 46] with slight modifications. Cells overexpressing either a Flag-IN or HAp75 were lysed in a 300 μl of the lysis buffer (500 mm NaCl, 50 mm HEPES (pH 7.8), 0.5% Triton X-100, 5% glycerol, 2 mm MgCl 2 ), and to this, 1.2 ml of a binding buffer (50 mm HEPES (pH 7.8), 5% glycerol, 2 mm MgCl 2 ) with or without indicated amount of 6d was added. The mixture was nutated at 4°C for 4 hr to allow binding of the compound. This was followed by the addition of a cell lysate containing the other protein partner and the nutation was continued at 4°C for 12 hr, for the complex to form. Anti-Flag beads (Clontech) were added to the mixed lysates and nutated at 4°C for additional 2 hr. Beads were washed with buffer containing 150 mm NaCl, 50 mm HEPES (pH 7.8), 0.1% Triton X-100, 0.1% NP-40, 5% glycerol and 2 mm MgCl 2 to remove any non-specific proteins. The proteins bound to the beads were eluted in a SDS-PAGE loading buffer and resolved on a 10% SDS-PAGE gel. The Flag-IN and HA-p75 bands were detected on a Western blot using anti-Flag (Clontech) and anti-HA (Thermo Scientific) antibodies, respectively.
| Infection of pseudo-typed HIV-1
The production of NLX-Luc-VSVg virus, setting up of infection and measuring of luciferase activity at 48 hr postinfection, in the HEK293T cells, was performed as described earlier, [47] with slight modifications. The growth media on HEK293T cells containing the virus was collected at 48 hr post-transfection and stored at −80°C till it is used for infecting the cells. For analysing the effect of 6d on the late stage of replication, the virus was generated by treating the HEK293T cells with 6d for the duration of transfection. In experiments analysing inhibition of the early stage of replication, cells were treated with 6d for 2 hr prior to the addition of virus. To set up an infection using 70 μl of the virus, 0.08-0.12 million cells were plated per well of a 24-well plate at least 12 hr in advance. At 48 hr postinfection, cells were harvested and the cell lysates was prepared using a 1× passive lysis buffer (Promega, cat. No. E1941). The luciferase activity in the lysates was measured using a D-luciferin sodium salt (Invitrogen, cat no. L2912). The luciferase activity was normalized to the concentration of the protein determined using a BCA reagent (Pierce, cat. No. 23221). The normalized luciferase activity in untreated infected cells was taken as 100% and that in 6d treated cells was determined accordingly. To measure the viability of cells treated with 6d, addition of virus was omitted in the above infection protocol, and at 48 hr post-treatment with 6d, a trypan blue exclusion method was used to determine the per cent of live cells. The number of live cells in untreated wells was set as 100% and that in 6d treated cells was determined accordingly.
| Molecular docking analysis
Molecular docking of 6d to CCD dimer of IN was performed using a discovery studio version 4.0 software (Accelrys, USA). The three-dimensional structure of CCD of IN (PDB accession 1BL3) [48] was used as a receptor and 6d was used as a ligand, in the LibDock protocol. The known LEDGF/p75 interacting residues of IN [12, 13, 21] : L102, A128, A129, W131, W132, E170, H171, T174 and M178 were used to define the interaction sphere for docking. The best-docked pose was ranked based on the LibDock score and binding energy and was used for determining the interactions between 6d and the CCD dimer.
| Statistical analysis
Intensity of the bands corresponding to IBD or LEDGF/p75 over IN (ratio of IBD or LEDGF/p75 to IN) was calculated to obtain the extent of complex formation in the pull-down assays. The IBD:IN ratio in the sample without compound was set to 100% binding and in those having compound was calculated accordingly. The concentration of a compound giving a 50% inhibition of the complex formation is determined to be its IC 50 . Data from at least three independent experiments have been used to obtain the standard error.
| RESULTS AND DISCUSSION
| Tetrahydroisoquinolines can inhibit interaction between IBD and IN in vitro
The first series of 1,2,3,4-tetrahydroisoquinoline compounds 1a-1m ( Figure S2 ) were tested in vitro for their ability to inhibit the interaction between His-IN and GST-IBD in the pull-down assay. A serial double dilution of the compounds with a starting concentration of 24 mm was used in the initial screening, and the in vitro assay was performed as described in the methods. The IC 50 of the compounds 1a-1m for inhibiting the formation of IBD-IN complex is shown in Table 1 . Of all the compounds tested in this series, 1a is found to be the most potent as it has the least IC 50 of ~80 μm (Figure 1a) . Although 1h has the second best IC 50 , 1d that differs from 1h only in the presence of an ethyl rather than a tert-butyl group on the ester moiety did not show any inhibition even at the highest concentration tested in the in vitro assay.
| Increasing the potency of compounds by rearranged aromatization
With the aim of increasing the potency of the compounds in the first series, either a reducing or an oxidizing condition was used as an additional step to the synthesis scheme and those compounds with an appreciable purity were tested in vitro. Reducing of the ester group on the best compound 1a (IC 50 ~80 μm) resulted in an alcohol containing derivative labelled as 4a (Scheme S2), that has an IC 50 greater than 24 mm, emphasizing the importance of an ester moiety for the activity of the compound. Subjecting 1a to an oxidative condition (Scheme S3) resulted in a rearranged aromatization and significantly enhanced the potency of the derivative labelled as 6a. Compound 6a showed the inhibition of IBD-IN complex formation with an IC 50 of 20.2 ± 8.1 μm (Figure 1b) . Interestingly, a similarly rearranged aromatization of 1d (that lacks any inhibitory activity, Table 1 ) resulted in a lead molecule 6d (ethyl-1-benzyl-7-methoxyisoquinoline-4-carboxylate) that is characterized further in this study.
Compound 6d inhibited the interaction between IBD and IN with an IC 50 of 10.4 ± 3.8 μm (Figure 1c ) and the interaction between IN and full-length LEDGF/p75 with an IC 50 of 11.1 ± 4.4 μm ( Figure S3 ). Thus, compared to 1d, a benzyl group at the 1st position of an unsaturated bicyclic system dramatically enhanced the ability of 6d for inhibiting the interaction between IBD and IN. 
| Molecular docking shows interaction of 6d with the critical residues of CCD
To gain insight into how 6d interacts with IN, molecular docking of 6d to CCD dimer of IN was performed as described in Section 2. The interactions between 6d and CCD are summarized in Table 2 . The results of docking analysis indicate that 6d inhibits binding of IBD by sterically blocking access to the LEDGF/p75 binding site on IN (Figure 1d ), similar to the LEDGINs reported earlier. Co-crystal structures of the known LEDGINs with CCD [23] [24] [25] [26] 30] reveal Hbonds between the carboxyl moiety of the inhibitor and the backbone amides of E170, H171 and the side chain hydroxyl group of T174, while 6d has pi-donor H-bonds between the isoquinoline core and the side chain hydroxyl group of T174. In addition, methoxy and ester moieties of 6d make carbon H-bond with the backbone amides of Q95 and A128, respectively. The quinoline core of known LEDGINs has a hydrophobic interaction with one face of the hydrophobic pocket of CCD dimer comprised of residues Q95, T124, T125, A128, while the isoquinoline core of 6d has a hydrophobic interaction with A98, A169 and T174. The ethyl group (in the ester moiety) of 6d is surrounded by the hydrophobic side chains of L102, W132 and M178. A pi-anion charge interaction is present between the benzyl group of 6d and the side chain carboxyl group of E170. Overall, the binding of 6d to CCD dimer while being similar to that of known LEDGINs seems to offer sufficient differences in the type of interactions at the LEDGF/p75 binding site that could potentially be explored further. It has been shown earlier that a virus resistant to LEDGINs carries one or more of the following mutations: Y99H, L102F, T124N, A128T, A129T, H171T, T174I in CCD, with A128T being the most common resistance mutation. [32, 49, 50] Owing to the overlap in the residues of CCD interacting with 6d and known LEDGINs, similar mutations in IN can be expected to result in an emergence of resistance to 6d.
| Binding of IBD, 6d to IN is mutually exclusive
To gain a further insight into the details of inhibition by 6d, IBD-IN or LEDGF/p75-IN complexes were formed in the absence of 6d and in the absence or presence of a non-specific DNA, and activity of 6d on such complexes was analysed. First, displacing of IBD in the complex by 6d would require accessing the same interacting residues on CCD, which might be feasible if 6d can also bind at a secondary site on IN and induce conformational changes in CCD that reduce the affinity for IBD. Second, as both IN and LEDGF/p75 are non-specific DNA binding proteins, [39] [40] [41] [42] [43] it is possible that a DNA bound protein has an altered affinity for 6d or DNA by itself binds to 6d, consequently influencing the activity of 6d.
Following the formation of a IBD-IN complex at 37°C for 10 min, 150 μm of 6d (15 times the IC 50 ) was added and pulldown assay was performed as described in the methods. As can be seen in Figure 2a decreases the effective concentration of 6d that is required to inhibit complex formation. Although full-length LEDGF/ p75 binds to a non-specific DNA, [42, 43] addition of 6d to a DNA bound LEDGF/p75 prior to that of IN (Figure 2b , lane 9) or vice versa (lane 10) did not result in an inhibition of the LEDGF/p75-IN complex formation. These results indicate that neither the presence of a non-specific DNA nor the binding of DNA by any of the protein partners, at any stage of the complex formation, interferes with the inhibitory activity of 6d in vitro.
| Inhibition of interaction in the presence of cellular proteins
Prior to testing the ability of 6d to inhibit HIV-1 infection, the inhibitory activity of 6d on an interaction between the ectopically expressed proteins in a mammalian cell lysate was A noticeable increase in the inhibitory potency of 6d could be seen as a 33 ± 2, 41 ± 8 and 75 ± 7% decrease in the infectivity of the virus generated in the presence of 12.5, 25 and 50 μm of 6d was observed (Figure 3b , filled triangles). An IC 50 of ~31 μm, with a selectivity index of 4.5, for inhibition of late stage of replication has been obtained. At concentrations above 50 μm, the cytotoxic effects of 6d interfered with the analysis of its inhibitory effects. These results indicate that, similar to the known LEDGINs, [23] [24] [25] [26] [27] [28] [29] [30] 6d could also be affecting both the LEDGF/p75-dependent integration rather than steps such as reverse transcription, nuclear import of PIC, during early stage of replication, while the virus generated in the presence of 6d could be less infectious due to an effect on the maturation stage, arising from the aberrant multimerization of IN (a LEDGF/p75-independent effect).
| CONCLUSIONS
In conclusion, compound 6d (ethyl-1-benzyl-7-methoxyisoquinoline-4-carboxylate) that efficiently inhibits the interaction between LEDGF/p75 and IN in vitro, as well as, HIV-1 infection in a cell line, has been identified as a lead isoquinoline molecule in this study. The order of addition experiment indicates an overlap in the binding site for IBD, 6d on CCD of IN. Similar to the known LEDGINs, [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] 6d shows an effect on the early and late stages of HIV-1 replication. In addition to the chemical differences between 6d and already known LEDGINs ( Figure  S1 ), molecular docking indicates a possibility for sufficient differences in the type of interactions between 6d and the residues of CCD ( Table 2) . Of interest is the ethyl group in the ester moiety of 6d which fits into the hydrophobic pocket of CCD that is occupied by the side chain of one of the critical residue I365 of LEDGF/p75. In a recent study, we have shown that M178 of CCD might probably be the first residue from the hydrophobic pocket of IN to interact with I365 of LEDGF/p75. [44] As the mutation of M178 is shown to result in a catalytically inactive IN, [51] as well as, result in an abrogation of its interaction with LEDGF/ p75, [44] the features of 6d imparting interaction with M178 could potentially be exploited further for developing a small molecule having higher potency and variation from the known LEDGINs.
